Kuros Biosciences AG

Kuros Biosciences AG

Health CarePharmaceuticals and Biotechnology
  • Price (CHF)1.80
  • Today's Change0.045 / 2.56%
  • Shares traded5.69k
  • 1 Year change-25.93%
  • Beta1.0098
Data delayed at least 15 minutes, as of Jul 05 2022 16:31 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

  • Revenue in CHF (TTM)13.82m
  • Net income in CHF-7.54m
  • Incorporated1995
  • Employees58.00
  • Location
    Kuros Biosciences AGWagistrasse 25SCHLIEREN 8952SwitzerlandCHE
  • Phone+41 447334747
  • Fax+41 447334740
  • Websitehttp://www.kuros.ch/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
MagForce AG352.62k-10.59m51.88m69.00--1.93--147.12-0.3531-0.35310.01180.89670.00553.470.85325,101.16-16.47-3.78-31.53-6.78-89.9525.30-3,004.22-295.230.0321-1.970.2485---43.33-5.77-171.71------
Francotyp Postalia Holding AG217.76m4.81m52.42m899.0010.702.412.150.24070.30010.300114.281.331.216.729.92241,792.002.67-0.87585.83-1.6353.1355.472.21-0.7530.8506--0.6663--4.010.0718102.38-42.60-12.39--
Partnera Oyj50.26m6.13m53.21m276.008.060.73315.221.060.17620.17751.371.940.35991.372.58--4.427.396.078.5654.4046.1012.2819.881.25--0.315--51.757.48-45.34-6.67180.51--
Renergetica SpA12.83m2.67m54.65m28.0020.474.3514.594.260.32930.32931.581.550.39620.37294.77465,706.208.16--10.63--55.95--20.60--2.044.390.5507--1,017.93--22.14------
Dedicare AB (publ)128.22m7.10m54.91m1.11k9.853.736.560.42838.128.12146.7021.472.63--4.991,491,009.0014.5415.6630.9729.88----5.545.00--25,195.250.173773.7941.2013.9781.804.3729.80-12.94
Blirt SA8.50m1.20m55.50m72.0045.839.0334.776.530.32510.32512.301.651.000.97647.69533,257.2014.1927.6315.8133.1176.5073.6014.1417.682.60--0.00---34.6352.11-66.00--60.72--
Exact Therapeutics AS0.00-5.66m55.59m8.00--4.20-----2.71-2.710.004.52------0.00--------------------0.0137-------123.18------
Territorial'naya Gnschy Kmpny 14 PAO223.51m2.19m57.10m5.61k27.220.4952.670.25550.000090.000090.00960.0051.055.6512.12--1.031.941.593.1051.97--0.9791.810.46630.5720.23540.001.790.9416-59.79-40.803.30--
Softline Holding Plc (GDR)1.67bn-1.39m57.21m5.93k--3.553.640.0343-0.0079-0.00799.440.3215------330,349.10--------15.34---0.0867--0.75671.830.8212--11.40---121.16------
Kuros Biosciences AG13.82m-7.54m57.58m58.00--0.7477--4.17-0.2369-0.23690.64572.350.14882.3310.13238,189.70-8.12-13.87-8.84-14.6972.86---54.59-269.992.76-11.140.0271--242.0467.0834.54--49.55--
4Basebio PLC-116.35bn-116.35bn59.48m---------------------------------------------------26.84---349.93------
Airthings ASA30.37m-6.89m59.53m125.00--1.01--1.96-0.4117-0.41171.813.500.43531.593.79---9.90---11.08--63.95---22.75--5.78------44.35---75.45------
eEducation Albert AB7.07m-6.90m60.57m----2.69--8.56-4.22-4.224.3213.70----------------113.90---97.64-----285.060.00--161.70---117.06------
Dovre Group Oyj143.00m3.67m61.03m486.0016.512.1011.800.42680.03480.03481.360.27372.50--6.22--7.553.7214.486.2567.8089.193.021.931.1213.250.229152.3184.2511.24123.19--3.75--
Generic Sweden AB (publ)11.09m1.73m64.22m19.0037.1919.5834.505.791.511.519.702.872.17136.1813.126,277,158.0033.8019.9450.1528.5946.5652.5215.5712.642.98--0.00113.4140.8817.3867.1928.85-16.7027.23
Ascelia Pharma AB0.00-11.73m64.95m21.00--2.49-----3.67-3.670.008.330.00----0.00-33.85---37.06--------------0.004-------27.57------
Data as of Jul 05 2022. Currency figures normalised to Kuros Biosciences AG's reporting currency: Swiss Franc CHF

Institutional shareholders

19.69%Per cent of shares held by top holders
HolderShares% Held
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 20213.28m9.99%
Banque Pictet & Cie SAas of 31 Dec 20211.39m4.25%
Apo Asset Management GmbHas of 31 Mar 20221.31m3.98%
UBS Asset Management Switzerland AGas of 31 May 2022199.94k0.61%
Schroder Investment Management (Switzerland) AGas of 30 Nov 2018123.81k0.38%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202070.55k0.22%
Migros Bank AGas of 30 Jun 202137.13k0.11%
BlackRock Asset Management Schweiz AGas of 02 Jun 202221.99k0.07%
Lombard Odier Asset Management (Switzerland) SAas of 29 Apr 202216.90k0.05%
Equinor Asset Management ASAas of 31 Dec 202113.75k0.04%
More ▼
Data from 31 Dec 2021 - 29 Apr 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.